ALMS has suffered one of the most violent single-week drawdowns in its short life as a public company, and the Street's response — a wave of target cuts filed within hours of each other — tells you everything about how sudden the reset has been.
The stock closed at $9.47 on September 1, down 57% on the day and 60% for the week. That is not a correction; it is a binary-event collapse. The one-month loss now stands at 66%, erasing a year-to-date gain that had reached north of 145% as recently as late August. Whatever clinical or regulatory development triggered the move, the market re-priced the equity almost instantaneously.
The analyst response has been uniform in direction if not in scale. Every firm that reported on September 2 cut its price target — none changed their positive rating. Morgan Stanley's Terence Flynn trimmed from $39 to $29 while holding Overweight. Wells Fargo's Derek Archila nearly halved his target, from $51 to $25, keeping Overweight. Oppenheimer cut hardest in absolute terms, from $55 to $37, maintaining Outperform. The one outlier was HC Wainwright, which actually upgraded to Buy from Neutral — cutting its target from $25 to $15 — a move that reflects the analyst's view that the stock has now over-discounted the bad news. With nine Buy ratings and zero Holds on the consensus panel, the Street is uniformly constructive in direction but scrambling to recalibrate on price. The mean target of $32.33 implies more than 240% upside from current levels — a gap that signals how far the stock has fallen relative to where analysts had been anchoring, not necessarily where it is headed.
The bull case rests on two TYK2 inhibitors — envudeucitinib and A-005 — with Phase 2 data in psoriasis and lupus that was, until this week, driving the year's outperformance. The bear case, now suddenly more relevant, centres on regulatory filing risk, competition from established biologics and newer oral therapies, and the company's dependence on finding a commercial partner for lonigutamab to avoid heavy equity dilution. The EPS surprise factor score, at the 87th percentile, suggests the company has a strong track record of beating estimates — but for a pre-profitability biotech burning cash (the P/E is deeply negative at -7.7x), estimate beats matter less than pipeline inflection points.
Short positioning tells a less alarming story than the price action alone might imply. Short interest rose 25% on the week to 6.2% of the free float — notable but not extreme, and still well below levels seen in late July when short interest was running closer to 13% of float. Borrow availability remains very loose at roughly 900% of current short interest, meaning there is no shortage of shares to lend and no squeeze dynamic at play. Cost to borrow is up 28% on the week but at just 0.58% it remains trivially low — this is not a crowded short with structural pressure behind it. The options put/call ratio at 0.51 is barely above its 20-day average of 0.49, suggesting options traders had not pre-positioned defensively ahead of whatever the trigger event was.
The ownership register complicates the picture in an important way. Three Schedule 13D filers — Srinivas Akkaraju, James B. Tananbaum, and AyurMaya Capital Management — are on record as activists, collectively owning close to 30% of the company. Tananbaum last filed in April at 12.7% of the class; AyurMaya filed in July at 12.3%. These are not passive index positions — they are concentrated, disclosed activist stakes. In January, Akkaraju and Foresite Capital entities bought shares at $17 in open-market transactions worth roughly $25 million combined, without a 10b5-1 plan. Those buys are now deeply underwater. The caveat applies: 13D positions are disclosed around the 5% threshold, and holders dropping below that level may not file again — but any response from these activists will be worth watching closely. FMR (Fidelity) added more than 5.7 million shares as recently as July, now holding 5.2% of the company — a position that also crystallised a major loss this week.
Next, the focus falls on what exactly drove the collapse — whether regulatory, clinical, or commercial — and whether the company's cash runway, combined with the concentrated activist ownership, produces a formal strategic response ahead of the November 13 earnings date.
See the live data behind this article on ORTEX.
Open ALMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
